Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Trial Profile

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Allotransplant rejection; Ataxia; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; Immune thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Focus Adverse reactions
  • Sponsors Baxalta; Shire
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 1 Jan 2020 to 31 Jan 2020.
    • 06 Nov 2017 Planned primary completion date changed from 1 Jan 2020 to 31 Jan 2020.
    • 24 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top